Here you can learn more about isotopic metallome, find our overviews, white papers, patents, third party research in support of our scientific stance, and many more...
Here you can learn more about isotopic metallome, find our overviews, white papers, patents, third party research in support of our scientific stance, and many more...
In Vitro Anticancer Activity of Light Stable Zinc Isotope (64Zn) Compounds
This publication presents evaluation of cytotoxic activity of our first therapeutic drug candidate based of light zinc isotope 64Zn enriched to >99% against MB16 melanoma and L1210 leukemia cells malignant cells.
First-in-Human Study of KLS-1 (64Zn L-Aspartate)
This publication presents our small, non-registrational, first-in-human "learning" study of our KLS-1 drug candidate (64Zn enriched to >99%) in patients with oncological and neurodegenerative diseases. The purpose of this study was to establish initial dose of KLS1 for treatment of patients with various pathologies prior to conducting full-scale registrational Phase 1 clinical trial.
Mitigating Neuroinflammatory Responses in AD through Microglia-Mediated Pathways
This publication discusses our study for KLS-1 administration in rats with Aβ1-40-induced Alzheimer's disease (AD.) The article outlines our perspective on targeting systemic and neuroinflammation in AD and presents findings from our preclinical investigation in this area. The purpose of this study was to assess the effect of intravenous administration of novel investigational drug substance, 64Zn aspartate (KLS-1), on local and systemic inflammation and on cognitive parameters in rats with Aβ1-40-induced AD.
Therapeutic Potential of Isotopically Modified 64Zn Aspartate for Obesity Management
This publication outlines our perspective on targeting obesity with the first-in-class, first-in-humans isotope selective modulator, KLS-1, and presents findings from our preclinical investigation in this indication. The purpose of this study was to assess the effect of 64Zn aspartate (KLS-1) on body mass, appetite, oxidative stress, and histopathological changes in pancreas and liver in Diet-Induced Obesity rodent model.
Treatment With Isotopically Modified 64Zinc-Aspartate Alleviates Neuroinflammation and Motor Dysfunction in PD
This white paper outlines our perspective on targeting systemic inflammation in Parkinson's disease (PD) and presents our preclinical findings. The purpose of this study was to assess the effect of intravenous administration of novel investigational drug substance, 64Zn aspartate (KLS-1), on local and systemic inflammation and on cognitive parameters in rats with LPS-induced PD.
Inflammatory Hallmarks in 6-OHDA- and LPS-induced Parkinson's Disease in Rats
Inflammatory Hallmarks in 6-OHDA- and LPS-induced Parkinson's Disease in Rats
This publication presents a comparison of activation patterns of microglia/macrophage population and systemic inflammation indices in rats with 6-Hydroxydopamine (6-OHDA)- and Lipopolysaccharide (LPS)-induced animal models of Parkinson's Disease. This is essential for maximizing the translation of their potential to the clinic, as well as for developing putative anti-inflammatory neuroprotective agents.
Systemic Inflammation in Aβ1-40-induced Alzheimer’s Disease Model: New Translational Opportunities
Systemic Inflammation in Aβ1-40-induced Alzheimer’s Disease Model: New Translational Opportunities
Neuroinflammation is associated with the impairment of blood–brain barrier and leakage of inflammatory mediators into the periphery with developing systemic inflammatory responses. Systemic inflammation is considered one of the therapeutic targets for AD treatment that necessitates in-depth study of this phenomenon in appropriate non-transgenic animal models. This publication discusses inflammation as one of the therapeutic targets for treatment of Alzheimer's disease (AD.)